Assessment of the in vitro and in vivo activity of atorvastatin against Candida albicans by Ajdidi, Ahmad et al.
1497
Assessment of the in vitro and in vivo activity of atorvastatin 
against Candida albicans
Ahmad Ajdidi1, Gerard Sheehan1, Khaled Abu Elteen2 and Kevin Kavanagh1,*
RESEARCH ARTICLE
Ajdidi et al., Journal of Medical Microbiology 2019;68:1497–1506
DOI 10.1099/jmm.0.001065
Received 10 April 2019; Accepted 07 August 2019; Published 28 August 2019
Author affiliations: 1SSPC Research Centre, Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland; 2Department of Biology and 
Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
*Correspondence: Kevin Kavanagh,  kevin. kavanagh@ nuim. ie
Keywords: atorvastatin; Candida; ergosterol; Galleria mellonella; infection; statin.
Abbreviations: AMP, antimicrobial peptide; BP, biological process; DEP, differentially expressed proteins; FDR, false discovery rate; GO, gene ontology; 
MP, molecular function; SSDA, statistically significant differentially abundant.
Three supplementary figures are available with the online version of this article.
001065 © 2019 The Authors
Abstract
Aim. The aim of this work was to characterize the response of Candida albicans to atorvastatin, and to assess its in vivo anti-
fungal capability.
Methodology. The effect of atorvastatin on the growth and viability of C. albicans was assessed. The ability of the statin to alter 
cell permeability was quantified by measuring amino acid and protein leakage. The response of C. albicans to atorvastatin was 
assessed using label-free quantitative proteomics. The in vivo antifungal activity of atorvastatin was assessed using Galleria 
mellonella larvae infected with C. albicans.
Results. Atorvastatin inhibited the growth of C. albicans. The atorvastatin-treated cells showed lower ergosterol levels than 
the controls, demonstrated increased calcofluor staining and released elevated quantities of amino acids and protein. Larvae 
infected with C. albicans showed a survival rate of 18.1±4.2 % at 144 h. In contrast, larvae administered atorvastatin (9.09 mg 
kg−1) displayed a survival rate of 60.2±6.4 % (P<0.05). Label-free quantitative proteomics identified 1575 proteins with 2 or 
more peptides and 465 proteins were differentially abundant (P<0.05). There was an increase in the abundance of enzymes 
with oxidoreductase and hydrolase activity in atorvastatin-treated cells, and squalene monooxygenase (4.52-fold increase) 
and lanosterol synthase (2.84-fold increase) were increased in abundance. Proteins such as small heat shock protein 21 
(−6.33-fold) and glutathione peroxidase (−2.05-fold) were reduced in abundance.
Conclusion. The results presented here indicate that atorvastatin inhibits the growth of C. albicans and is capable of increasing 
the survival of G. mellonella larvae infected with C. albicans.
InTRoduCTIon
The yeast Candida albicans induces a wide range of superficial 
and life-threatening systemic infections in susceptible patients 
[1]. C. albicans possesses an extensive repertoire of virulence 
factors that allow successful colonization and dissemination in 
the host [1] and these include the ability to adhere to host tissue, 
produce a range of enzymes (e.g. secreted aspartyl proteinase, 
phospholipase), form biofilms and alter phenotype to overcome 
the host’s immune response [2, 3]. Conventional antifungal 
therapy relies upon the use of polyene, azole or echinocandin 
drugs, but the delivery of appropriate therapy is often problem-
atic due to the appearance of resistance and the inherent toxicity 
of some antifungal therapies [4].
Statins (e.g. atorvastatin, lovastatin, pravastatin and simvas-
tatin) are one of the most widely prescribed medications and 
lower cholesterol levels in blood by inhibiting the action of 
3-hydroxy-3-methylglutaryl-CoA (HMG-Co A) reductase 
[5, 6]. Fungal HMG-CoA reductases are also inhibited by 
statins, which results in a reduction in ergosterol content and 
the inhibition of fungal growth [5]. Statins inhibit the growth 
of a wide range of medically important fungi (e.g. Aspergillus 
fumigatus and C. albicans), but not Candida krusei [6], 
and supplementation of statin-containing growth medium 
with ergosterol leads to the recovery of growth, indicating 
that statins specifically inhibit the mevalonate pathway [7]. 
Prolonged exposure of Candida glabrata cells to statins leads to 
an increase in the percentage of petite (respiratory-deficient) 
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mutations in the population, suggesting that statins may also 
affect the integrity of mitochondrial DNA [8].
Patients on statin therapy experience fewer fungal infections 
[9], suggesting that statins may be capable of inhibiting the 
growth of fungi in vivo and so may represent a novel, non-
toxic antifungal treatment option [10, 11]. In addition, the 
administration of statins to patients with severe sepsis [12] 
or bacteraemia [13] results in increased survival, possibly 
due to a reduction in inflammatory responses [14]. The aim 
of the work presented here was to characterize the effect of 
atorvastatin on C. albicans and establish its in vivo antifungal 
activity using Galleria mellonella larvae.
METHodS
Fungal cultures
C. albicans MEN was maintained on yeast extract–peptone–
dextrose (YEPD) agar and grown for approximately 24 h in 
YEPD broth [2 % (w/v) glucose, 2 % (w/v) bacteriological 
peptone (Difco Laboratories), 1 % (w/v) yeast extract (Oxoid 
Ltd, Basingstoke, UK] to the stationary phase (approximately 
2×108 ml−1). C. albicans cells were washed twice in sterile 
phosphate-buffered saline (PBS) before use and enumerated 
by haemocytometry.
Atorvastatin
Atorvastatin (20 mg film-coated; Rowex Ltd) tablets were 
ground to a fine powder and dissolved in sterile PBS. The 
solution was filter-sterilized using 0.45 and 0.02 µm pore 
filters (Sarstedt). The tablets contained the following excipi-
ents – sodium lauryl sulfate, microcrystalline cellulose, 
silica, colloidal anhydrous, pregelatinized maize starch, 
trometamol, yellow iron oxide (E 172), magnesium stearate 
and talc sodium starch glycolate (coating: carmellose sodium, 
glycerol, trometamol, sodium lauryl sulfate and hydroxyethyl 
cellulose) – and in vitro testing revealed no antifungal activity 
of these agents at the concentrations used in the tablets.
Assessment of effect of atorvastatin on growth of 
C. albicans
The effect of atorvastatin on the growth of the C. albicans 
was assessed using the broth microdilution technique (Docu-
ment M27, Clinical and Laboratory Standards Institute) [15]. 
Stationary-phase C. albicans cells were harvested, washed in 
PBS (5 ml) and resuspended in medium at a concentration 
of 5×106 cells ml−1. The cell suspension (100 µl) was added to 
each well of a 96-well plate containing various concentrations 
of statin in 100 µl of YEPD. The plate was incubated at 30 °C 
for 24 h. The optical density at 540 nm was determined using 
a microplate reader (Beckman DU 640 spectrophotometer) 
and growth was quantified as a percentage of the control [15].
Effect of atorvastatin on the viability of C. albicans
C. albicans cells were incubated in 10 ml PBS supplemented 
with atorvastatin (6, 12 and 24 µg ml−1) for 2, 4 and 24 h at 
30 °C. Aliquots (20 µl) were removed and serially diluted, and 
100 µl of diluted sample was spread onto YEPD agar plates. 
The resulting colonies were enumerated and expressed as % 
survival relative to the control (n=3).
Ergosterol extraction and quantification
Ergosterol was extracted from C. albicans cells as described 
[16]. Ergosterol quantification was performed using a gas 
chromatograph (Hewlett Packard 5890 series II) with a 
flame ionization detector and a chrompack capillary column 
(Chrompack International BV, Middleburg, The Nether-
lands). The carrier gas was N2, and the injector and detector 
temperatures were set at 320 °C. Ergosterol standards were 
used to calibrate the instrument.
determination of amino acid leakage
Amino acid leakage from C. albicans cells exposed to atorv-
astatin (12 µg ml−1) for 0 to 4 h at 30 °C was determined using 
the ninhydrin colorimetric method and expressed in terms 
of aspartic acid and glutamic acid [17]. Ninhydrin (Sigma-
Aldrich) was dissolved in ethanol to give a final concentration 
of 0.35 % (w/v) and 250 µl was added to each sample (1 ml) 
and heated to 95 °C for 4 min followed by cooling on ice. The 
absorbance at 570 nm was recorded on a spectrophotometer 
(Beckman DU 640).
Assessment of protein release
Stationary-phase C. albicans cells were exposed to atorvas-
tatin (12 µg ml−1) for 0 to 4 h at 30 °C. Cells were harvested 
by centrifugation at 3000 g and the supernatants were 
collected. The quantity of protein released from the cells in 
the supernatant was assayed using the Bradford assay (Bio-
Rad), with bovine serum albumin (BSA) (Sigma-Aldrich) 
as standard.
Fluorescence microscopy
C. albicans cells were grown in the presence of atorvastatin 
(6, 12 and 24 µg ml−1) for 24 h, harvested by centrifugation, 
washed in PBS and stained with calcofluor white (Sigma) for 
15 min at 16 °C on a glass slide. Cells were washed twice (PBS) 
and a cover slide was placed on top. Cells were viewed with 
an Olympus BX51 fluorescence microscope.
Adherence assay
The adherence of C. albicans to buccal epithelial cells (BECs) 
was analysed as described [18]. Cells pre-grown overnight 
in atorvastatin-supplemented medium (12 µg ml−1) were 
harvested, washed in PBS and resuspended at a density 
of 5×105 ml−1. C. albicans cells were mixed with BECs at a 
ratio of 50 : 1 in a final volume of 2 ml and incubated at 30 °C 
and 200 r.p.m. for 90 min. The BEC–yeast cell mixture was 
harvested by passage through a polycarbonate membrane 
and placed on glass slides to air-dry overnight. Cells were 
heat-fixed and stained using 0.5 % (w/v) crystal violet. The 
number of C. albicans cells adhering to each of 200 BECs per 
treatment was assessed microscopically.
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Assessment of in vivo toxicity of atrovastatin in G. 
mellonella larvae
G. mellonella larvae were obtained from the Meal Worm 
Company (Sheffield, UK) and stored in wood shavings in 
the dark at 15 °C prior to use as described [19, 20]. Larvae 
weighing 0.22±0.03 g were used within 2 weeks of receipt 
and 10 healthy larvae per treatment and controls (n=3) were 
placed in sterile 9 cm Petri dishes containing some wood 
shavings. Larvae of G. mellonella were inoculated with atro-
vastatin solution (20 µl of 50 or 100 µg ml−1) through the last 
left proleg and survival was monitored over 144 h at 30 °C.
Assessment of in vivo anti-fungal activity of atorvastatin 
using G. mellonella larvae
Larvae were administered 20 µl solution containing 1×106C. 
albicans cells ml−1 through the last left proleg as described 
[19]. Treated larvae were administered 20 µl of atorvastatin 
(4.55 or 9.09 mg kg−1) 30 min post-infection with C. albicans 
and the survival of larvae was monitored over 144 h at 30 °C. 
The aim of this work was to replicate the situation in practice 
where the administration of agent(s) occurs after infection.
Label-free quantitative proteomics analysis of C. albicans
Label-free shotgun semi-quantitative proteomics was 
conducted on C. albicans cells pre-grown in the presence of 
atrovastatin (12 µg ml−1) for 24 h (n=4). Protein was extracted 
as described [19, 20] and protein (75 µg) was reduced with 
dithiothreitol (DTT; 200 mM) (Sigma-Aldrich), alkylated 
with iodoacetamide (IAA; 1 M) (Sigma-Aldrich) and 
digested with sequence grade trypsin (Promega, Ireland) at 
a trypsin : protein ratio of 1 : 40, overnight at 37 °C. Tryptic 
peptides were purified for mass spectrometry using C18 spin 
filters (Medical Supply Company, Ireland) and 1 µg of peptide 
mix was eluted onto a Q-Exactive (Thermo Fisher Scientific, 
USA) high-resolution accurate mass spectrometer connected 
to a Dionex Ultimate 3000 (RSLCnano) chromatography 
system. Peptides were separated by an increasing acetonitrile 
gradient on a Biobasic C18 Picofrit column (100 mm length, 
75 mm ID) using a 65 min reverse-phase gradient at a flow rate 
of 250 nl min−1. All data were acquired with the mass spec-
trometer operating in automatic data-dependent switching 
mode. A high-resolution mass spectrometer scan (300–2000 
Dalton) was performed using the Orbitrap to select the 15 
most intense ions prior to tandem mass spectrometry.
Protein identification from the tandem mass spectrometry 
data was performed using the Andromeda search engine in 
MaxQuant (version 1.2.2.5; http:// maxquant. org/) to correlate 
the data against the proteome of C. albicans obtained from 
Uniport. The following search parameters were used: first 
search peptide tolerance of 20 p.p.m., second search peptide 
tolerance of 4.5 p.p.m., carbamidomethylation of cysteines 
set as a fixed modification, with oxidation of methionines 
and acetylation of N-terminals set as variable modifications, 
and a maximum of two missed cleavage sites allowed. False 
discovery rates (FDRs) were set to 1 % for both peptides 
and proteins and the FDR was estimated following searches 
against a target–decoy database. Peptides with a minimum 
length of seven amino acids were considered for identification 
and proteins were only considered to have been identified 
when more than one unique peptide for each protein was 
observed.
Results processing, statistical analyses and graphics generation 
were conducted using Perseus v. 1.5.5.3. Label-free quantifica-
tion (LFQ) intensities were log2-transformed and analysis of 
variance (ANOVA) of significance and t-tests between the 
proteome of the 24 h control and the atrovastatin-treated 
(12 µg ml−1) C. albicans were performed using a P-value of 
0.05 and significance was determined using FDR correction 
(Benjamini–Hochberg). Proteins that had non-existent values 
(indicative of absence or very low abundance in a sample) 
were also used in statistical analysis of the total differentially 
expressed group following imputation of the zero values using 
a number close to the lowest value of the range of proteins 
plus or minus the standard deviation. After data imputa-
tion these proteins were included in subsequent statistical 
analysis. Blast2GO software was applied to determine gene 
ontology (GO) terms relating to biological processes (BPs) 
and molecular function (MF).
Statistical analysis
All experiments were performed on three independent occa-
sions and the results are expressed as the mean±sd. Statistical 
significance in the growth assay, viability assay, ergosterol 
quantification and leakage experiments was assessed by t-test. 
Larval survival was assessed by Kaplan–Meier log rank. All 
statistical analysis was performed using GraphPad Prism. 
Differences were considered significant at P≤0.05.
data availability
The MS proteomics data and MaxQuant search output files 
have been deposited at the ProteomeXchange Consortium 
[21] via the PRIDE partner repository with the dataset identi-
fier PXD013365.
RESuLTS
Analysis of the effect of atorvastatin on the growth 
and viability of C. albicans
Cells of C. albicans were exposed to atorvastatin and growth 
was assessed after 24 h. The results revealed that a dose of 
96 µg ml−1 reduced growth by 74.6±0.3 % at 24 h (P<0.0001) 
(Fig. 1). Concentrations of 12 and 24 µg ml−1 reduced growth 
by 11.9±1.1 % and 21.8±0.5 % (P<0.05), respectively, at 24 h. 
Exposure of Escherichia coli or Staphylococcus aureus to ator-
vastatin resulted in no inhibition of growth (Fig S1, available 
in the online version of this article). The effect of atorvastatin 
on the viability of C. albicans was also assessed and the results 
revealed a small fungicidal effect (Fig S2). Exposure of cells 
to 24 µg ml−1 atorvastatin reduced viability by 19±1.6 % at 4 h 
and by 22.5±0.9 % at 24 h.
Exposure of C. albicans to atorvastatin (12 µg ml−1) for 
24 h led to a reduction in the ergosterol content of cells 
[control=0.063±0.008 µg ml−1 and treatment=0.027±0.003 
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µg ml−1 (P=0.04) (Fig. 2]. Experiments to assess the extent 
of leakage from atorvastatin-treated cells were performed. 
Exposure of cells to atorvastatin (12 µg ml−1) for up to 4 h led 
to an increase in amino acid (Fig. 3a) and protein (Fig. 3b) 
leakage from cells. Exposure to atorvastatin for 2 and 4 h led 
to an amino acid concentration of 1.97±0.09 µg ml−1 and 
1.78±0.1 µg ml−1, respectively. Protein release at 2 and 4 h was 
147.7±10.8 and 132.7±18.1 µg ml−1, respectively, while for the 
control it was 57.3±6.2 and 35.67±4.6 µg ml−1, respectively 
(P<0.05).
Altered membrane permeability could lead to distortions in 
the fungal cell wall. Staining cells with calcofluor following 
exposure to atorvastatin revealed increased fluorescence, 
indicating an increase in the chitin content of cells. Atorvas-
tatin-treated cells also appeared to be larger and demonstrated 
incomplete cell separation (Fig. 4). Atorvastatin-treated cells 
demonstrated a reduced ability to adhere to exfoliated buccal 
epithelial cells, indicating a possible disruption to the surface 
of the yeast cell (Fig S3). Control cells showed 5.55±0.6 yeast 
cells adhering per BEC, while cells exposed to atorvastatin 
showed 3.02±0.5 adhering per BEC (P=0.009)
Assessment of toxicity and in vivo antifungal 
efficacy of atrovastatin
The administration of doses of atorvastatin (4.55 or 9.09 mg 
kg−1) to G. mellonella larvae by intrahaemocoel injection 
resulted in no adverse effect over 144 h (Fig.  5). Larvae 
infected with C. albicans were subsequently administered a 
dose of atorvastatin (4.55 or 9.09 mg kg−1) 30 min post-infec-
tion (Fig. 5). The results indicate increased survival in those 
larvae given a dose of atorvastatin (4.55 or 9.09 mg kg−1). 
Larvae infected with C. albicans showed a survival rate of 
76.8±3.5 % at 72 h and one of 18.1±4.2 % at 144 h. In contrast, 
those larvae administered a 9.09 mg kg−1 dose of atorvastatin 
displayed a survival rate of 94.3±1.96 % at 72 h and one of 
60±6.4 % at 144 h (P<0.05).
Proteomic analysis of the effect of atorvastatin on 
C. albicans
Comparative analysis of differential protein abundance in 
atorvastatin-treated C albicans was performed using label-
free proteomics. A principal component analysis (PCA) was 
Fig. 1. Effect of atorvastatin on growth of C. albicans. C. albicans (initial concentration 104 per well) was exposed to atorvastatin (0.75 – 
195 μg ml−1) in YEPD. Growth (%) was calculated by comparing atorvastatin-treated C. albicans to control cells after 24 h of growth (*, 
P<0.05; **, P<0.01; ***, P<0.001).
1501
Ajdidi et al., Journal of Medical Microbiology 2019;68:1497–1506
performed on all filtered proteins and identified distinct 
proteomic differences between the control and statin-treated 
samples (Fig. 6a). The heat maps also show major differences 
in the relative abundance of proteins in the control and 
atorvastatin-treated cells (Fig.  6b). In total, 1575 proteins 
with 2 or more peptides were identified and 465 proteins 
were determined to be differentially abundant (ANOVA, 
P<0.05) with a fold change of >1.5. Of these, 231 were found 
in higher abundance in the atorvastatin-treated cells and 
234 were present in lower abundance in the treated cells. A 
total of 74 proteins were present in all 3 control samples and 
absent in all 3 treated samples, and a further 57 were present 
in each replicate of the atorvastatin treatment and absent in 
all 3 control samples.
The volcano plot (Fig.  6c) shows the relative increase or 
decrease in the abundance of proteins in the atorvastatin-
treated cells compared to the control cells. A variety of 
proteins were increased in abundance in atorvastatin-treated 
cells and these included squalene monooxygenase ERG1 
(4.52-fold), lanosterol synthase (3.30-fold), 3-keto-steroid 
reductase (2.78-fold), lanosterol 14-alpha demethylase 
(2.57-fold) and acetyl-CoA C-acetyltransferase (2.23-fold). 
A number of proteins were decreased in abundance in the 
Fig. 2. Atorvastatin exposure reduced the ergosterol content of C. albicans. Ergosterol quantification was performed using a gas 
chromatogram with a flame ionization detector and a chrompack capillary column. Ergosterol standards were used to calibrate the 
instrument. Ergosterol content was expressed in terms of μg ml−1 (*, P<0.05).
Fig. 3. Effect of atorvastatin on the release of amino acids (a) and protein (b) from C. albicans. The effect of atorvastatin (12 μg ml−1) on 
C. albicans amino acid and protein release was determined by ninhydrin colorimetric assay and Bradford protein assay. Atorvastatin 
treatment resulted in increased amino acid and protein release relative to control cells (*, P<0.05; **, P<0.01; ***, P<0.001).
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treated cells, including Hsp12p (−6.33-fold), small heat shock 
protein 21 (-6.26-fold), yeast-form wall protein 1 (−5.68-
fold), Wh11p (−4.93-fold), Acyl-CoA desaturase (−4.88-fold) 
and heat shock protein SSA1 (−4.40-fold). Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) analysis of proteins 
that showed altered abundance in atorvastatin-treated cells 
revealed seven proteins that showed increased abundance 
in the fungal steroid pathway (Fig. 7). This suggests that the 
cell may be attempting to increase ergosterol biosynthesis or 
redirect biosynthesis following the inhibition of the action of 
the fungal 3-hydroxy-3-methylglutaryl-CoA reductase.
dISCuSSIon
Statins are widely used for the control of cholesterol and 
function by inhibiting the action of HMG-Co A (3-hydroxy-
3-methylglutaryl-CoA) reductase [22]. The long term use of 
statins is generally regarded as safe [23], but there is evidence 
to suggest immune modulatory effects in certain patients 
[24, 25] and, in particular, the induction of alterations in the 
activity of regulatory T-cells [26].
Cholesterol in mammals and ergosterol in fungi share a similar 
structure and biosynthetic pathways and consequently both 
pathways are sensitive to the same inhibitory effects of statins 
[27, 28]. Patients on statin therapy display fewer fungal infec-
tions, thus prompting the suggestion that statins may have 
potential applications as anti-fungal agents in vivo [6, 9]. This 
raises the possibility that statins, in addition to being used to 
control cholesterol levels, may also be used in the control of 
fungal infections either as sole therapies or in combination 
with existing antifungal therapies [6]. For example, statins 
could be useful in the treatment of fungal pathogens showing 
resistance to conventional antifungal agents (e.g. azoles). The 
work presented here evaluated the interaction of atorvastatin 
Fig. 4. Calcofluor staining of C. albicans following exposure to atorvastatin. (Magnification x 400). C. albicans cells were exposed to 
atorvastatin (6, 12 and 24 μg ml−1) for 24 h, stained with calcofluor white and visualized with an Olympus BX51 fluorescence microscope. 
Increased fluorescence indicated an increase in the chitin content of cells.
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with C. albicans and demonstrated the in vivo activity of the 
statin against C. albicans infection in G. mellonella larvae.
In this work atorvastatin tablets were ground to a fine powder, 
added to a volume of water and filter-sterilized prior to use. 
Some loss of product could have occurred during the filtra-
tion process, but this was not considered to be significant. 
The exposure of C. albicans to atorvastatin reduced growth 
and also caused a small reduction in viability. Statins reduce 
cholesterol biosynthesis in vivo [22] and also reduced the 
ergosterol content in C. albicans. Ergosterol plays a key role 
in maintaining the integrity and permeability of the fungal 
cell membrane and reduced levels of ergosterol could indicate 
a more porous membrane [9, 23]. Statin exposure did lead to 
an increase in the release of amino acid and proteins from 
cells, indicating increased permeability.
Atorvastatin-treated cells displayed elevated levels of chitin, 
were larger than untreated cells and demonstrated incomplete 
cell division. Interestingly, proteomic analysis revealed that 
glutamine-fructose-6-phosphate aminotransferase, an enzyme 
that plays a role in chitin synthesis and hyphal growth, was 
increased in abundance (+2.29-fold) in atorvastatin-treated 
cells. Adherence to host cells is an important virulence factor of 
C. albicans [29] and is mediated by a variety of specific and non-
specific mechanisms. The dominant adherence mechanism is 
mediated by cell wall-bound adhesins that attach to host cell 
receptors and anchor the cell in hostile environments to form 
a focal point for tissue invasion. The exposure of C. albicans to 
atorvastatin led to a reduction in the adherence ability of cells, 
possibly as a consequence of the altered cell wall composition, 
as indicated by the increased calcofluor staining. Proteomic 
analysis revealed decreased abundance of yeast-form wall 
protein (−6.26-fold), which plays a role in adherence and the 
promotion of dispersal and in Wh11p (−5.68-fold), a protein 
involved in biofilm formation and pathogenesis.
A number of proteins involved in the ability of the cell to 
respond to stress were reduced in abundance. Heat shock 
proteins such as Hsp12p (−6.33-fold), small heat shock 
protein 21 (-6.33-fold) and heat shock protein SSA1 (−4.40-
fold) were reduced in abundance and these play roles in the 
pathogenicity of the yeast and in its ability to respond to 
oxidative and osmotic stress. Reduced abundance of these 
proteins may have an impact on the cell’s ability to grow and 
proliferate in vivo. Proteins such as Cip1p (−3.73-fold), Pst2p 
(−3.01-fold), pleiotropic ABC efflux transporter (−2.85-fold) 
were also reduced in abundance and all play a role in the cell’s 
response to oxidative stress [30].
Proteomic analysis revealed an increase in the abundance of 
proteins involved in ergosterol biosynthesis in atorvastatin-
treated cells. In particular, squalene monooxygenase (+4.52-
fold), lanosterol synthase (+3.30-fold), keto-steroid reductase 
(+2.78-fold) and lanosterol 14-alpha demethylase (+2.57-
fold) were all increased in abundance. Atorvastatin-treated 
cells displayed reduced ergosterol content and perhaps the 
cells responded to statin exposure by attempting to increase 
its biosynthesis. Statins inhibit the synthesis of important 
isoprenoids, e.g. farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate, which are lipid attachments for the γ subunit 
of heterotrimeric G-proteins [31], guanosine triphosphate-
binding protein Ras and Ras-like proteins (Rho, Rab, Rac, Ral, 
or Rap) [31–33]. Moreover, statins act as inhibitors of some 
G-protein actions and Ras or Ras-like signalling, which affect 
several important bioprocesses [34].
Fig. 5. Effect of atorvastatin on viability of G. mellonella larvae infected with C. albicans. Larvae injected with atorvastatin (4.55 or 9.09 mg 
kg−1) displayed no decrease in survival. Larvae were inoculated with C. albicans (1×106 larva−1) and then treated with atorvastatin (4.55 or 
9.09 mg kg−1) 30 min later, and survival was monitored over 144 h. Atorvastatin (4.55 or 9.09 mg kg−1) treatment enhanced larval survival 
relative to non-treated larvae.
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G. mellonella larvae can be employed to assess the virulence 
of fungal pathogens [35, 36] and determine the in vivo activity 
of antifungal agents [37, 38]. Their use offers the possibility 
of quickly establishing the in vivo toxicity and efficacy of 
antimicrobial agents without the need to resort to the use of 
mammals in initial screening studies. In the work presented 
here atorvastatin was shown to be non-toxic to larvae and to 
be able to protect larvae following infection with C. albicans. 
The doses of 50 and 100 μg ml−1 used in the larvae are equiva-
lent to 4.55 and 9.09 mg kg−1 in humans, respectively. Interest-
ingly, atorvastatin had a negative effect on the survival of mice 
infected with C. albicans and followed up with atorvastatin 
(40 mg kg−1), and this was due to decreased INF-gamma and 
IL-4 levels in response to C. albicans, while the LD50 for ator-
vastatin is 5000 mg kg−1 in mice [39]. However, other work 
has demonstrated that pravastatin enhanced survival and 
led to a decreased fungal burden in C3H/HeN mice infected 
with C. albicans and the potential benefits of statins in the 
clinic against Candida have been described [10, 40–42]. The 
proteomic results indicated reduced abundance of proteins 
associated with virulence and stress response (e.g. Hsp12p 
and ABC efflux transporter) in C. albicans and this may 
have made the cells more susceptible to killing by the larval 
immune response.
Fig. 6. Shotgun proteomics of responses of C. albicans to atorvastatin (12 μg ml−1) after 24 h at 30 °C. (a) Principal component analysis of 
the control and atorvastatin-treated C. albicans over 24 h showed a clear distinction between the control and treated C. albicans. (b) Two-
way unsupervised hierarchical clustering of the median protein expression values of all statistically significant differentially abundant 
proteins from the C. albicans control (C1, C3 and C4) and the atorvastatin-treated (T1, T2 and T4) C. albicans. (c) Volcano plot showing the 
distribution of quantified proteins according to P-value (−log
10
 P-value) and fold change (log
2
 mean LFQ intensity difference). Proteins 
above the horizontal line are considered statistically significant (P-value <0.05) and those to the right and left of the vertical lines indicate 
relative fold changes ±1.5.
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The results presented here indicate that atrovastatin has a 
profound effect on C. albicans, reducing its ability to grow 
and increasing its susceptibility to killing in the G. mellonella 
larval model system. While the anti-microbial activity of 
statins are well established, this work demonstrates how 
they interact with the fungal proteome to induce their 
effects and highlights their ability to retard proliferation 
in vivo. The continuing problems associated with existing 
antifungal therapies (e.g. toxicity and drug resistance) make 
the possibility of employing an active, non-toxic therapy such 
as atorvastatin to supplement existing therapies particularly 
attractive [5, 6].
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